Menu Search
Equities

Phibro Animal Health Corp

PB8:DUS

Phibro Animal Health Corp

Actions
  • Price (EUR)22.60
  • Today's Change0.20 / 0.89%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

  • Revenue in USD (TTM)1.05bn
  • Net income in USD17.41m
  • Incorporated2014
  • Employees1.94k
  • Location
    Phibro Animal Health Corp300 Frank W. Burr Blvd.Suite 21, 65 Challenger RoadTEANECK 07666United StatesUSA
  • Phone+1 (201) 329-7300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pahc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.